Browse the full management transaction log of Patterson Companies, INC., a listed issuer based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Patterson Companies, INC. has recorded 51 reports. The latest transaction was reported on 18 April 2022 — Cession. Among the most active insiders: POHLMAN KEVIN M. The full history is accessible without an account.
25 of 51 declarations
Patterson Companies, Inc. is a U.S.-listed healthcare distribution and services company traded on the NASDAQ under the ticker PDCO. For international investors, it is a long-established but relatively niche participant in the North American healthcare supply chain, focused on dental and animal health customers. The company is headquartered in Saint Paul, Minnesota, and its operating model is built around logistics, field sales, product availability, and customer support rather than high-margin branded manufacturing. Patterson positions itself as a partner to dental practices and veterinary professionals by combining products, technology, and service capabilities. ([sec.gov](https://www.sec.gov/Archives/edgar/data/891024/000089102424000008/pdco-20240427.htm?utm_source=openai)) Patterson’s roots date back to the nineteenth century, and over time it evolved into a two-segment business: Patterson Dental and Patterson Animal Health. The dental business serves dentists and dental clinics with equipment, consumables, instruments, digital solutions, and related services. The animal health business supplies veterinarians and animal health professionals with pharmaceuticals, consumables, equipment, and operational support tools. This dual-market structure gives Patterson exposure to end markets that are generally resilient and recurring, but still highly competitive. The company competes against specialized distributors, direct manufacturers, and increasingly digital or e-commerce channels, which keeps pricing discipline and service quality important to the investment case. ([sec.gov](https://www.sec.gov/Archives/edgar/data/891024/000089102424000008/pdco-20240427.htm?utm_source=openai)) Geographically, Patterson has a broad footprint across North America, particularly the United States and Canada, and it also serves parts of the U.K. through its animal health activities. Its competitive edge is not based on scale alone; it comes from distribution breadth, customer relationships, technical sales coverage, and added-value services that help practices run more efficiently. At the same time, this model carries exposure to supplier concentration, margin pressure, logistics execution, and the ongoing shift toward online purchasing and private-label or direct-to-customer alternatives. Recent company commentary has emphasized operational discipline, product innovation, and customer support across both end markets. ([sec.gov](https://www.sec.gov/Archives/edgar/data/891024/000119312524208250/d888887dex99.htm?utm_source=openai)) Recent developments have been especially important. In December 2024, Patterson announced a definitive merger agreement with Patient Square Capital, under which the private equity firm would acquire Patterson for $31.35 per share in an all-cash deal valued at roughly $4.1 billion, including refinancing of receivables facilities. During fiscal 2025, the company also highlighted the impact of a cybersecurity-related disruption tied to Change Healthcare on earnings, while continuing to return cash to shareholders through dividends and share repurchases. In early 2025, Patterson reported quarterly results showing softer sales trends but continued focus on execution while progressing toward the proposed transaction. For investors, the current story is therefore a mix of stable end-market exposure, moderate operating pressure, and a major corporate event that could redefine the stock’s future. ([sec.gov](https://www.sec.gov/Archives/edgar/data/891024/000089102425000003/pdco-20250125.htm?utm_source=openai))